Atomo Diagnostics Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Atomo Diagnostics's earnings have been declining at an average annual rate of -4.6%, while the Medical Equipment industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 5.7% per year.
Key information
-4.6%
Earnings growth rate
11.0%
EPS growth rate
| Medical Equipment Industry Growth | 5.8% |
| Revenue growth rate | 5.7% |
| Return on equity | -67.9% |
| Net Margin | -167.6% |
| Next Earnings Update | 30 Jan 2025 |
Recent past performance updates
Recent updates
We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth
Jul 05
We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth
Oct 10Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?
Jun 10We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn
Dec 06Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 01We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow
Jul 19Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)
Feb 26Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business
Jan 22Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like
Dec 18
When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?
Jul 16Revenue & Expenses Breakdown
How Atomo Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4 | -7 | 5 | 0 |
| 31 Mar 24 | 4 | -7 | 6 | 0 |
| 31 Dec 23 | 3 | -7 | 6 | 0 |
| 30 Sep 23 | 3 | -9 | 6 | 0 |
| 30 Jun 23 | 3 | -10 | 7 | 1 |
| 31 Mar 23 | 5 | -9 | 7 | 1 |
| 31 Dec 22 | 8 | -9 | 7 | 1 |
| 30 Sep 22 | 10 | -7 | 7 | 1 |
| 30 Jun 22 | 12 | -6 | 7 | 1 |
| 31 Mar 22 | 10 | -6 | 7 | 1 |
| 31 Dec 21 | 7 | -6 | 7 | 1 |
| 30 Sep 21 | 7 | -6 | 7 | 1 |
| 30 Jun 21 | 7 | -6 | 6 | 1 |
| 31 Mar 21 | 8 | -8 | 6 | 1 |
| 31 Dec 20 | 9 | -10 | 6 | 1 |
| 30 Sep 20 | 7 | -9 | 5 | 1 |
| 30 Jun 20 | 5 | -9 | 4 | 1 |
| 31 Mar 20 | 3 | -7 | 4 | 1 |
| 31 Dec 19 | 1 | -5 | 3 | 1 |
| 30 Sep 19 | 1 | -5 | 3 | 1 |
| 30 Jun 19 | 1 | -5 | 3 | 1 |
| 30 Jun 18 | 0 | -5 | 2 | 3 |
| 30 Jun 17 | 0 | -5 | 2 | 3 |
Quality Earnings: AT1 is currently unprofitable.
Growing Profit Margin: AT1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AT1 is unprofitable, and losses have increased over the past 5 years at a rate of 4.6% per year.
Accelerating Growth: Unable to compare AT1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AT1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.7%).
Return on Equity
High ROE: AT1 has a negative Return on Equity (-67.9%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 08:14 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atomo Diagnostics Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanushree Jain | Bell Potter |
| Martyn Jacobs | Canaccord Genuity |